Efficient Sensing of a 4-Segmented Rift Valley Fever Virus Vaccine Candidate by Human Monocytes.

The live-attenuated RVFV-4s vaccine against Rift Valley fever has demonstrated safety and efficacy across multiple animal models and in a phase 1 clinical trial. In this study, we examined its impact on innate immune responses and found that RVFV-4s enhances the expression of costimulatory molecules critical for T-cell activation, while triggering proinflammatory responses in primary human monocytes.